The Cytotoxic T Lymphocyte Antigen-4+49A/G Single Nucleotide Polymorphism Association With Visceral Leishmaniasis by Hajilooi, M. et al.
Jundishapur J Microbiol.2014 October; 7(10):e12143. DOI: 10.5812/jjm.12143Published online 2014 October 1. Research ArticleThe Cytotoxic T Lymphocyte Antigen-4 +49A/G Single Nucleotide Polymorphism Association With Visceral Leishmaniasis
Mehrdad Hajilooi 1; Pegah Lotfi 2; Farhad Seif 3; Ahad Bazmani 4; Mohammad Momeni 5; Ali Ravary 6; Mohammad Kazemi Arababadi 5; Ali Reza Khalilian 7,*
1Department of Immunology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, IR Iran2Department of Microbiology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, IR Iran3Department of Immunology and Microbiology, Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, IR Iran4Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran5Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran6Occupational Environment Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, IR Iran7Faculty of Medicine, Shahid Beheshti Hospital, Hamadan University of Medical Sciences, Hamadan, IR Iran 
*Corresponding author: Ali Reza Khalilian, Shahid Beheshti Hospital, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, IR Iran. Tel: +98-8118271560, Fax: +98-8118254073, E-mail: immunology86@yahoo.com
 Received: June 10, 2013; Revised: August 04, 2013; Accepted: September 10, 2013
Background: Several lines of evidence approve that innate and adaptive immunity play key roles in the defense against visceral leishmaniasis (VL). The polymorphism within the cytotoxic T lymphocyte antigen 4 (CTLA-4) gene alters its expression.
Objectives: The main aim of this study was to evaluate the polymorphism within the +49 position of the CTLA-4 gene of Iranian patients with VL in comparison with healthy controls.
Materials and Methods: In this cross-sectional study, 88 patients with clinical presentations of VL, who were seropositive for Leishmania (group 1), 86 patients without clinical presentations but seropositive (group 2), and 115 healthy controls (group 3) were assessed with respect to the CTLA-4 +49A/G polymorphism, using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The anti-Leishmania antibody titration was evaluated using an immunofluorescence method.
Results: Our results indicated that both CTLA-4 +49A/G polymorphisms were significantly associated with VL.
Conclusions: According to the results, the polymorphisms within the +49 position of CTLA-4 can be associated with VL and may be considered as risk factors for the disease.
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1. BackgroundSeveral Leishmania species are responsible for leishman-iasis, a vector-borne parasitic disease (1). Previous investi-gations demonstrated that although the sand fly vector is the main cause of Leishmania transmission into humans (1), the parasite can also be transmitted via blood trans-fusions (2), needlestick injury (3), or the mother/child route during pregnancy (4). Various clinical manifesta-tions, including cutaneous, mucocutaneous, and visceral forms of the disease (5) are plausible after Leishmania infection, among which the visceral form (also known as Kala Azar) is the most severe form that can be lethal if left untreated (6). The quality and quantity of host immune system against the infection determines the final clinical outcome and severity of the disease (7).T lymphocytes play key roles in combating against leishmaniasis via cytokine production (T-helper cells) and killing the parasite (8). Cytotoxic T lymphocyte an-tigen 4 (CTLA-4) is expressed on activated T cells and in-teracts with CD80 and CD86, which also are ligands for CD28, resulting in inhibition of T lymphocytes functions 
(9). Based on its important roles in T lymphocyte suppres-sion, it appears that CTLA-4 plays key roles in inducing peripheral tolerance against self and foreign antigens, which are seen in self-tolerance and chronic infections, respectively. Therefore, genetic variations that lead to up-regulation of this molecule can be associated with immune suppression and chronic infections, includ-ing visceral leishmaniasis (VL). Previous studies showed that the CTLA-4 gene contained several polymorphisms including CTLA-4 A/G and T/C at the +49 position (refer-ence single nucleotide polymorphisms (SNP): (rs) 231775) (10). Additionally, CTLA-4 +49 A allele resulted in increase of CTLA-4 expression (11, 12). Hence, it appears that this al-lele increases the inhibitory function of CTLA-4 on T cell proliferation and leads to attenuated immune responses against infections.
2. ObjectivesDue to the fact that the quality and quantity of immune responses identify the outcome of leishmaniasis, the 
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main aim of this study was to evaluate the CTLA-4 +49A/G polymorphism in seropositive patients with VL with and without clinical presentation, in comparison with healthy controls.
3. Materials and Methods
3.1. SubjectsIn this cross-sectional study, 88 patients with VL with antibody against Leishmania (seropositive) (group 1), 86 seropositive healthy controls (group 2), and 115 sero-negative healthy controls (group 3) were recruited for sample donation. VL was diagnosed by an expert special-ist according to laboratory findings, medical histories, and clinical presentations. The patients with VL as well as both groups 2 and 3 were selected from Meshkin city (north–west of Iran), where Leishmania infantum is en-demic (13-15), while other species have not been report-ed. The Ethical Committee of the Ardabil University of Medical Sciences approved the study protocol and the participants filled out informed consent forms prior to entrance in the study.
3.2. DNA ExtractionGenomic DNA was purified from peripheral blood sam-ples, which were obtained from the participants in eth-ylene diamine tetra acetic acid (EDTA) pretreated tubes, using a commercial kit from Bioneer Company (South Korea) according to the manufacturer’s instructions.
3.3. Polymorphism DetectionThe CTLA-4 +49A/G gene polymorphism was examined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. PCR was per-formed in a final volume of 20 µL, containing 0.3 µL Taq DNA polymerase (5 U), 2 Μl Taq DNA polymerase buffer 
(10x), 2 μL of each primer (25 ng/μL), 1 μL of each dNTP 
[(dATP, dCTP, dGTP, dTTP) at a concentration of 10 mM], 2 μL MgCl2 (stock concentration: 1.5 mM), 1 μL of prepared DNA and sterile double distilled DNase free water. All the ma-terials were purchased from Cinna Clone company (Iran). Sequences of forward and reverse primers (Cinna Clone, Iran) for amplification of the CTLA-4 +49A/G-containing region (162 bp) were 5'- GCTCTACTTCCTGAAGACCT-3' and 5'- AGTCTCACTCACCTTTGCAG-3', respectively. The follow-ing program was used for PCR amplifications: 95°C for five minutes (denaturation), followed by 35 cycles of 30 seconds at 95°C, 53°C for 30 seconds, and 72°C for 40 sec-onds, using a thermal cycler (Bioneer, South Korea). BbvI restriction enzyme (Cinna Clone, Iran) was ob-tained from Fermentas Company (Finland) and was used to recognize the polymorphism at the +49position. BbvI digested the PCR products of CTLA-4 +49A/G-containing position (162 bp), in the case of G allele, into 91 bp and 71 bp sub-fragments. RFLP was performed according to the 
manufacturer's guidelines. Briefly, 2 U of BbvI restriction 
enzyme and 5 μL of its associated buffer were added to 
10 μL of the PCR products and incubated for 16 hours in room temperature. A 2.5% pretreated ethidium bromide agarose gel (CinnaClone, Iran) was used for electrophore-sis of the PCR products and RFLP digestion products.
3.4. Immun of Luorescence AssayThe titration of the anti-Leishmania antibody was ana-lyzed using a commercial kit from QIAGEN Company (USA), according to the manufacturer’s guidelines. Briefly, a serial dilution of each participant's serum was prepared and the latest reacted concentration was determined as the anti-Leishmania titration.
3.5. Statistical AnalysisHardy-Weinberg equilibrium analysis was used for evaluating the validity of the data. χ2 test was used from the SPSS software version 13 to identify the differences be-tween the groups and P value less than 0.05 was consid-ered significant.
4. ResultsOur results indicated that CTLA-4 +49A/G polymor-phism was significantly associated with VL (P < 0.001). The results from the PCR-RFLP analysis demonstrated that the CTLA-4 +49-A/G genotype significantly increased in group 1 compared to both groups 2 and 3. The results in detailed are presented in Table 1 and Table 2. The statis-tical analysis demonstrated that the differences between the groups regarding the genotypes and alleles were sig-nificant (Tables 1 and 2). The current results also demon-strated that the patients with VL (group 1) carrying the CTLA-4 +49-A/G genotype had higher mean anti-Leish-
mania antibody titers; the statistical analysis revealed that the difference was significant (Table 3) (P < 0.001). The results also demonstrated that the titration of anti-
Leishmania antibody was significantly higher in group 3 participants carrying the CTLA-4 +49-A/G genotype than CTLA-4 +49-A/A and G/G genotypes (Table 3) (P < 0.001).
Table 1.  The Prevalence of CTLA-4 +49A/G Polymorphism Among Patients With Clinical Presentation of VL who Were Seropositive for Leishmania (Group 1), Without Clinical Presentation but Se-ropositive (Group 2), and healthy controls (Group 3) a,b
Group 1 Group 2 Group 3
GenotypesA/A 33 (37.5) 52 (60.5) 48 (41.7)A/G 48 (54.5) 22 (25.6) 22 (19.1)G/G 7 (8) 12 (14) 45 (39.1)
AllelesA 114 (64.8) 126 (73.3) 118 (51.3)G 62 (35.2) 46 (26.7) 112 (48.7)a Abbreviations: A, adenine; G, guanidine.b Data are presented as No. %
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Table 2. Comparisons of Group 1 versus Group 2 and Group 1 Versus Group 3 a
Genotypes Group 1 vs Group 2 Group 1 vs Group 3
OR (95% CI) P Value OR (95% CI) P Value
A/G-G/G 3.74 (1.29-10.79) 0.013 14.02 (5.46-36), P = 0.0001
A/A-G/G 1.09 (0.38-3.04) 0.87 4.42 (1.77-10.99) P = 0.001
A/A-A/G 0.29 (0.15-0.56) 0.0001 0.31 (0.16-0.61), P = 0.001a Abbreviations: A, adenine; G, guanidine; vs, versus.
Table 3. Anti-Leishmania Antibody Titration in Groups 1 and 2 Carrying Various CTLA-4 +49 Genotypes a,b,c,d
Anti-Leishmania Antibody Titration P Value
CTLA-4 +49-A/A CTLA-4 +49-A/G CTLA-4 +49-G/G
Group 1 2.3 ± 0.273 e 4.98 ± 0.216 1.86 ± 0.508 P < 0.001
Group 2 1.88 ± 0.14 f 3.32 ± 0.24 0.75 ± 0.15 P < 0.001a Sincegroups 1 and 2 had anti-Leishmania antibody, the relationship between the anti-Leishmania antibody titration and CTLA-4 +49 genotypes were performed within groups 1 and 2.b  Data are presented as labeled mean ± standard error.c The titrations were labeled with the following numbers: 0: no antibody, 1: 1/10, 2: 1/20, 3: 1/40, 4: 1/80, 5: 1/160, and 6: 1/320.d Group 1, seropositive patients with VL; group 2, seropositive healthy controls.e The differences between CTLA-4 +49-A/G and A/A genotypes were significant.f The differences among CTLA-4 +49- A/A, A/G and G/G genotypes were significant.
5. DiscussionCTLA-4 is expressed on activated T lymphocytes and binds to CD80 and CD86, which results in suppression of the T lymphocyte function (16). Ectopic up-regulation of CTLA-4 during infectious diseases results in impaired immune responses and consequently induces chronic forms of infectious diseases (17). Previous studies dem-onstrated that expression of CTLA-4 was regulated by the polymorphisms within the exon 1 (+49 position) region of the CTLA-4 gene (11, 12). Our results showed that either genotypes or alleles of CTLA-4 +49A/G polymorphism were significantly associated with VL in the Iranian popu-lation. Additionally, the current results revealed that the CTLA-4 +49-A/G genotype was significantly increased in group 1 compared to groups 2 and 3. As mentioned in the introduction section, the CTLA-4 +49 A allele was associat-ed with higher expression of CTLA-4; hence, it seems that higher prevalence of CTLA-4 +49-A/G genotype in Iranian patients with VL may be responsible for impaired im-mune responses against Leishmania in patients with VL. Previous studies demonstrated that CTLA-4 plays a cru-cial role in suppression of immune responses against 
Leishmania during VL (18). Elevation levels of CTLA-4 in patients with VL were also reported by Katara and col-leagues (19). Studies on animal models also revealed that CTLA-4 suppresses the immune responses against Leish-
mania via inducing the transforming growth factor-β (TGF-β), an anti-inflammatory cytokine (20). Murphy et al. showed that using anti-CTLA-4 antibody for blocking CTLA-4 led to enhanced host resistance to L. donovani (21). Murray and colleagues also identified that using anti-CTLA-4 antibody in L. donovani viscerally infected animals 
led to parasite killing by the immune cells (22). Another study by Saha et al. demonstrated that CTLA-4 may play key roles in regulation of T-helper 1/T-helper 2 balance, which is important to determine the leishmaniasis out-come (23). Another study by Zubairi and colleagues re-vealed that immunotherapy with anti-CTLA-4 increased the immune responses, which resulted in killing L. don-
ovani (24). Therefore, based on the aforementioned stud-ies, it seems that overexpression of CTLA-4 can be consid-ered as a main reason for impaired immune responses, in which, different CTLA-4 +49 genotypes may be respon-sible for up-regulation of this molecule in VL. To the best of our knowledge this was the first study eval-uating the CTLA-4 +49A/G polymorphism in leishmaniasis. However, there have been several studies on other chron-ic infections. For example, Danilovic et al. demonstrated that CTLA-4 +49A/G polymorphism was significantly as-sociated with chronic hepatitis C infection (25). Duan and colleagues reported that patients with chronic HBV infec-tion had higher frequencies of CTLA-4 +49-A/A genotype and also A allele (26). Raitala et al. evaluated the activity of 
Helicobacter pylori (HP), inducing indoleamine 2,3-dioxy-genase, in patients with chronic HP infections and found that the activity significantly increased in patients carry-ing CTLA-4 +49-A/A genotype (17). Therefore, based on the aforementioned study, CTLA-4 +49-A/G polymorphism can be significantly associated with chronic infections. These results confirmed the fact that the CTLA-4 +49A/G poly-morphism plays a key role in VL pathogenesis.Our results also showed that theCTLA-4 +49A/G poly-morphism was significantly associated with anti-Leish-
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mania antibody titrations in groups 1 and 2 participants; hence, this polymorphism can be associated with anti-body production against Leishmaniain Iranian patients. The results demonstrated that anti-Leishmania antibody titration significantly increased in either group1 or 2 with A/G genotype. Therefore, it appears that A/G genotype not only can be considered as a risk factor for VL, but can be associated with higher antibody production against 
Leishmania, which may be related to shift immune re-sponses of T-helper 2 immunity and consequently im-paired cellular immunity. Finally, based on our results, it seems that the CTLA-4 +49A/G polymorphism is signifi-cantly associated with VL as well as antibody production against Leishmania in Iranian patients with VL.
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